

HBsAg II

Hepatitis B surface antigen

cobas®

REF		SYSTEM
04687787 190	100	Elecsys 2010 MODULAR ANALYTICS E170 cobas e 411 cobas e 601 cobas e 602

English

Intended use

Immunoassay for the in vitro qualitative determination of hepatitis B surface antigen (HBsAg) in human serum and plasma.

The electrochemiluminescence immunoassay "ECLIA" is intended for use on Elecsys and **cobas e** immunoassay analyzers.

Regulatory approval

This assay has been CE marked according to Directive 98/79/EC. Test performance has been established and certified by a Notified Body according to the Common Technical Specifications (CTS) for diagnostic use and for screening of blood donations.

Summary

The hepatitis B surface antigen, a polypeptide of varying size, is a component of the external envelope of the hepatitis B virus particle (HBV).¹ The blood of persons infected with HBV contains, in addition to intact infectious HBV particles, smaller non-infectious "empty" envelope particles, which are formed in great excess and also contain the hepatitis B surface antigen.² The HBsAg determinant **a**, against which the immune response is mainly directed, is common to all HBsAg particles. Within this **a** determinant several HBsAg subtype determinants could be defined as **d**, **y**, **w1-w4**, **r** and **q**.³ Under selective pressure (caused by antiviral therapy or by the action of the immune system itself) the virus can express many different viable HBsAg mutants (so-called *escape mutants*). Some mutants might lead to a loss of detection in commercially available HBsAg assays.⁴ The Elecsys HBsAg II assay was especially developed in order to detect a multitude of these mutants.

The detection of HBsAg in human serum or plasma indicates an infection by the hepatitis B virus. HBsAg is the first immunological marker and is generally present some days or weeks before clinical symptoms begin to appear. HBsAg is observed in persons with acute and chronic hepatitis B infections.

HBsAg tests are used within the scope of diagnostic procedures to identify persons infected with HBV and to prevent the transmission of the hepatitis B virus by blood and blood products.

HBsAg tests are also used to monitor the course of the disease in persons with acute or chronic HBV infections⁵ and if necessary, to check the efficacy of an antiviral therapy.⁶ In addition, HBsAg tests are recommended as part of prenatal care, in order to be able to initiate suitable measures for preventing as far as possible the transmission of an HBV infection to the newborn child.^{7,8}

The Elecsys HBsAg II assay uses monoclonal and polyclonal anti-HBsAg antibodies (mouse and sheep) for the HBsAg determination.

Test principle

Sandwich principle. Total duration of assay: 18 minutes.

- 1st incubation: 50 µL of sample, two biotinylated monoclonal anti-HBsAg antibodies, and a mixture of monoclonal anti-HBsAg antibody and polyclonal anti-HBsAg antibodies labeled with a ruthenium complex^{a)} form a sandwich complex.
- 2nd incubation: After addition of streptavidin-coated microparticles, the complex becomes bound to the solid phase via interaction of biotin and streptavidin.
- The reaction mixture is aspirated into the measuring cell where the microparticles are magnetically captured onto the surface of the electrode. Unbound substances are then removed with ProCell/ProCell M. Application of a voltage to the electrode then induces chemiluminescent emission which is measured by a photomultiplier.

- Results are determined automatically by the software by comparing the electrochemiluminescence signal obtained from the reaction product of the sample with the signal of the cutoff value previously obtained by calibration.

a) Tris(2,2'-bipyridyl)ruthenium(II)-complex (Ru(bpy)₃²⁺)

Reagents - working solutions

The reagent rackpack (M, R1, R2) is labeled as HBSAG II.

- M Streptavidin-coated microparticles (transparent cap), 1 bottle, 6.5 mL: Streptavidin-coated microparticles 0.72 mg/mL; preservative.
- R1 Anti-HBsAg-Ab~biotin (gray cap), 1 bottle, 8 mL: Two biotinylated monoclonal anti-HBsAg antibodies (mouse) > 0.5 mg/L; phosphate buffer 100 mmol/L, pH 7.5; preservative.
- R2 Anti-HBsAg-Ab~Ru(bpy)₃²⁺ (black cap), 1 bottle, 7 mL: Monoclonal anti-HBsAg antibody (mouse), polyclonal anti-HBsAg antibodies (sheep) labeled with ruthenium complex > 1.5 mg/L; phosphate buffer 100 mmol/L, pH 8.0; preservative.

HBSAG II Cal1 Negative calibrator 1 (white cap), 2 bottles of 1.3 mL each: Human serum; preservative.

HBSAG II Cal2 Positive calibrator 2 (black cap), 2 bottles of 1.3 mL each: HBsAg approximately 0.5 IU/mL in human serum; preservative.

Precautions and warnings

For in vitro diagnostic use.

Exercise the normal precautions required for handling all laboratory reagents.

Disposal of all waste material should be in accordance with local guidelines. Safety data sheet available for professional user on request.

All human material should be considered potentially infectious.

The calibrators have been prepared exclusively from the blood of donors tested individually and shown to be free from HBsAg (HBSAG II Cal1 only) and antibodies to HCV and HIV.

The testing methods applied were FDA-approved or cleared in compliance with the European Directive 98/79/EC, Annex II, List A.

The serum containing HBsAg (HBSAG II Cal2) was inactivated using β-propiolactone and UV-radiation.

However, as no inactivation or testing method can rule out the potential risk of infection with absolute certainty, the material should be handled with the same level of care as a patient specimen. In the event of exposure, the directives of the responsible health authorities should be followed.^{9,10}

Avoid foam formation in all reagents and sample types (specimens, calibrators and controls).

Reagent handling

The reagents in the kit are ready for use and are supplied in bottles compatible with the system.

Elecsys 2010 and **cobas e 411** analyzers: The calibrators should only be left on the analyzers during calibration at 20-25 °C. After use, close the bottles as soon as possible and store upright at 2-8 °C.

Due to possible evaporation effects, not more than 5 calibration procedures per calibrator bottle set should be performed.

MODULAR ANALYTICS E170, **cobas e 601** and **cobas e 602** analyzers: Unless the entire volume is necessary for calibration on the analyzers, transfer aliquots of the ready-for-use calibrators into empty snap-cap bottles

HBsAg II

Hepatitis B surface antigen

(CalSet Vials). Attach the supplied labels to these additional bottles. Store the aliquots at 2-8 °C for later use.

Perform **only one** calibration procedure per aliquot.

All information required for correct operation is read in from the respective reagent barcodes.

Please note: Both the vial labels, and the additional labels (if available) contain 2 different barcodes. The barcode between the yellow markers is for **cobas** 8000 systems only. If using a **cobas** 8000 system, please turn the vial cap 180° into the correct position so the barcode can be read by the system. Place the vial on the instrument as usual.

Storage and stability

Store at 2-8 °C.

Do not freeze.

Store the Elecsys reagent kit **upright** in order to ensure complete availability of the microparticles during automatic mixing prior to use.

Stability of the reagent rackpack	
unopened at 2-8 °C	up to the stated expiration date
after opening at 2-8 °C	8 weeks
on MODULAR ANALYTICS E170, cobas e 601 and cobas e 602	4 weeks
on Elecsys 2010 and cobas e 411	4 weeks
on Elecsys 2010 and cobas e 411	6 weeks if stored alternately in the refrigerator and on the analyzers (up to 42 hours at 20-25 °C)

Stability of the calibrators	
unopened at 2-8 °C	up to the stated expiration date
after opening at 2-8 °C	8 weeks
on Elecsys 2010 and cobas e 411 at 20-25 °C	up to 5 hours
on MODULAR ANALYTICS E170, cobas e 601 and cobas e 602 at 20-25 °C	use only once

Store calibrators **upright** in order to prevent the calibrator solution from adhering to the snap-cap.

Specimen collection and preparation

Only the specimens listed below were tested in a sufficient number and found acceptable.

Serum collected using standard sampling tubes or tubes containing separating gel.

Li-heparin, EDTA- and citrate-plasma and plasma collected in tubes containing separating gel.

Criterion: Correct assignment of negative and positive samples.

Stable for 5 days at 2-8 °C, 3 months at -20 °C. The samples may be frozen 4 times.

The sample types listed were tested with a selection of sample collection tubes that were commercially available at the time of testing, i.e. not all available tubes of all manufacturers were tested. Sample collection systems from various manufacturers may contain differing materials which could affect the test results in some cases. When processing samples in primary tubes (sample collection systems), follow the instructions of the tube manufacturer.

Centrifuge samples containing precipitates before performing the assay.

Do not use heat-inactivated samples.

Do not use samples and controls stabilized with azide.

Ensure the samples, calibrators and controls are at 20-25 °C prior to measurement.

Due to possible evaporation effects, samples and calibrators on the analyzers should be analyzed/measured within 2 hours.

Materials provided

See "Reagents – working solutions" section for reagents.

- 2 x 6 bottle labels

Materials required (but not provided)

- [REF] 04687876190, PreciControl HBsAg II, for 8 x 1.3 mL each of PreciControl HBsAg II 1 and 2
- [REF] 11820648122, HBsAg Confirmatory Test, 2 x 1 mL each of confirmatory and control reagent
- [REF] 11776576322, CalSet Vials, 2 x 56 empty snap-cap bottles
- General laboratory equipment
- Elecsys 2010, MODULAR ANALYTICS E170 or **cobas e** analyzer
- Accessories for Elecsys 2010 and **cobas e** 411 analyzers:
 - [REF] 11662988122, ProCell, 6 x 380 mL system buffer
 - [REF] 11662970122, CleanCell, 6 x 380 mL measuring cell cleaning solution
 - [REF] 11930346122, Elecsys SysWash, 1 x 500 mL washwater additive
 - [REF] 11933159001, Adapter for SysClean
 - [REF] 11706802001, Elecsys 2010 AssayCup, 60 x 60 reaction vessels
 - [REF] 11706799001, Elecsys 2010 AssayTip, 30 x 120 pipette tips
- Accessories for MODULAR ANALYTICS E170, **cobas e** 601 and **cobas e** 602 analyzers:
 - [REF] 04880340190, ProCell M, 2 x 2 L system buffer
 - [REF] 04880293190, CleanCell M, 2 x 2 L measuring cell cleaning solution
 - [REF] 03023141001, PC/CC-Cups, 12 cups to prewarm ProCell M and CleanCell M before use
 - [REF] 03005712190, ProbeWash M, 12 x 70 mL cleaning solution for run finalization and rinsing during reagent change
 - [REF] 12102137001, AssayTip/AssayCup Combimagazine M, 48 magazines x 84 reaction vessels or pipette tips, waste bags
 - [REF] 03023150001, WasteLiner, waste bags
 - [REF] 03027651001, SysClean Adapter M
- Accessories for all analyzers:
 - [REF] 11298500316, ISE Cleaning Solution/Elecsys SysClean, 5 x 100 mL system cleaning solution

Assay

For optimum performance of the assay follow the directions given in this document for the analyzer concerned. Refer to the appropriate operator's manual for analyzer-specific assay instructions.

Resuspension of the microparticles takes place automatically prior to use. Read in the test-specific parameters via the reagent barcode. If in exceptional cases the barcode cannot be read, enter the 15-digit sequence of numbers.

Bring the cooled reagents to approximately 20 °C and place on the reagent disk (20 °C) of the analyzer. Avoid foam formation. The system automatically regulates the temperature of the reagents and the opening/closing of the bottles.

Place the calibrators in the sample zone.

All the information necessary for calibrating the assay is automatically read into the analyzer.

After calibration has been performed, store the calibrators at 2-8 °C or discard (MODULAR ANALYTICS E170, **cobas e** 601 and **cobas e** 602 analyzers).

Calibration

Traceability: This method has been standardized against the NIBSC standard (code number: 00/588; WHO Second International Standard for HBsAg, subtype adw2, genotype A; IU/mL).

The following reference materials from the Paul-Ehrlich-Institute, Langen (Germany), were also measured (U/mL) and compared with the WHO standard:

PEI Standard AD (information sheet 1985, subtype AD; 1000 U/mL; inactivated)

PEI Standard AY (information sheet 1985, subtype AY; 1000 U/mL; inactivated)

HBsAg II

Hepatitis B surface antigen

(1 IU/mL WHO Standard corresponds to 0.34 U/mL PEI Standard AY and 1 IU/mL WHO Standard corresponds to 0.44 U/mL PEI Standard AD)

Calibration frequency:

Calibration must be performed once per reagent lot using HBSAG II Cal1, HBSAG II Cal2 and fresh reagent (i.e. not more than 24 hours since the reagent kit was registered on the analyzer).

Renewed calibration is recommended as follows:

- after 1 month (28 days) when using the same reagent lot
- after 7 days (when using the same reagent kit on the analyzer)
- as required: e.g. quality control findings with PreciControl HBsAg II outside the defined limits
- more frequently when this is required by pertinent regulations

Range for the electrochemiluminescence signals (counts) for the calibrators:

Negative calibrator (HBSAG II Cal1): 600-1700,
positive calibrator (HBSAG II Cal2): 3000-11000.

Quality control

For quality control, use PreciControl HBsAg II.

Controls for the various concentration ranges should be run individually at least once every 24 hours when the test is in use, once per reagent kit, and following each calibration.

The control intervals and limits should be adapted to each laboratory's individual requirements. Values obtained should fall within the defined limits. Each laboratory should establish corrective measures to be taken if values fall outside the defined limits.

If necessary, repeat the measurement of the samples concerned.

Follow the applicable government regulations and local guidelines for quality control.

Note:

For technical reasons re-assigned target values valid only for a specific reagent and control lot combination, must be entered manually on all analyzers (except for the **cobas e 602** analyzer). Therefore always refer to the value sheet included in the reagent kit or PreciControl kit to make sure that the correct target values are used.

When a new reagent or control lot is used, the analyzer will use the original values encoded in the control barcodes.

Calculation

The analyzer automatically calculates the cutoff based on the measurement of HBSAG II Cal1 and HBSAG II Cal2.

The result of a sample is given either as reactive or non-reactive as well as in the form of a cutoff index (signal sample/cutoff).

Interpretation of the results

Samples with a cutoff index < 0.90 are non-reactive in the Elecsys HBsAg II assay. These samples are considered negative for HBsAg and do not need further testing.

Samples having a cutoff index in the range ≥ 0.90 to < 1.0 are considered borderline in the Elecsys HBsAg II assay.

Samples with a cutoff index ≥ 1.0 are considered reactive.

All initially reactive or borderline samples should be redetermined in duplicate using the Elecsys HBsAg II assay. If cutoff index values < 0.90 are found in both cases, the sample is considered negative for HBsAg. Initially reactive or borderline samples giving cutoff index values of ≥ 0.90 in either of the redeterminations are considered repeatedly reactive. Repeatedly reactive samples must be investigated using an independent neutralization test (Elecsys HBsAg Confirmatory Test).

Samples confirmed by neutralization with human anti-HBs are regarded as positive for HBsAg.

Limitations - interference

The assay is unaffected by icterus (bilirubin < 684 $\mu\text{mol/L}$ or < 40 mg/dL), hemolysis (Hb < 1.24 mmol/L or < 2 g/dL), lipemia (triglycerides < 22.8 mmol/L or < 2000 mg/dL) and biotin (< 164 nmol/L or < 40 ng/mL).

Criterion: Correct assignment of negative and positive samples.

Samples should not be taken from patients receiving therapy with high biotin doses (i.e. > 5 mg/day) until at least 8 hours following the last biotin administration.

No interference was observed from rheumatoid factors up to a concentration of 6210 IU/mL.

No false negative result due to high-dose hook effect was found with the Elecsys HBsAg II assay up to a concentration of 1.5 million IU/mL.

There is no indication for a significant loss in sensitivity or specificity with samples having elevated levels of IgM up to 3678 mg/dL, IgA up to 3250 mg/dL and IgG up to 3817 mg/dL.

No significant interfering effects of 21 commonly used therapeutic drugs could be detected.

According to the present state of knowledge, it can be assumed that available assays for the detection of HBsAg cannot identify all infected blood samples or persons. A negative test result does not exclude with certainty a possible exposure to or an infection with the hepatitis B virus. Negative test results obtained for persons with a past exposure may be caused by an antigen concentration below the detection limit of this assay or the lack of reactivity of the antigens to the antibodies used in this assay.

In rare cases, interference due to extremely high titers of antibodies to analyte-specific antibodies, streptavidin or ruthenium can occur. These effects are minimized by suitable test design.

MODULAR ANALYTICS E170, **cobas e 601** and **cobas e 602** analyzers:

Make sure that in the Special Wash List (Screen → Utility → Special Wash → Immune) the Elecsys HBsAg II assay is combined with all assays performed on the analyzer - including the Elecsys HBsAg II assay itself:

From test	Step	To test	Step 0	Step 1	Step 2
HBsAg II	1	HBsAg II	x	x	x
HBsAg II	1	each other assay	x	x	x

If new tests are installed make sure that the Special Wash List is updated accordingly.

For the Elecsys Anti-HBs assay make sure that "Step 1" and "Step 2" are activated:

From test	Step	To test	Step 0	Step 1	Step 2
Anti-HBs	1	HBsAg II	-	x	x

The described additions to the Special Wash List have to be entered manually. Please refer to the operator's manual.

For diagnostic purposes, the results should always be assessed in conjunction with the patient's medical history, clinical examination and other findings.

Limits and ranges

Detection limit

In order to determine the sensitivity, the HBsAg concentration which corresponds to the measuring signal of the cutoff value was read off the standard curves of serial dilutions of HBsAg standards (ad and ay) in human HBV-negative serum.

	Paul-Ehrlich-Institute standards				WHO standard 00/588	
	Subtype ad, 1985		Subtype ay, 1985		Subtype ad	
Sample	COI	U/mL	COI	U/mL	COI	IU/mL
1	88.4	1.999	566	10.0	39.4	2.00
2	44.7	1.005	289	5.04	19.9	0.998
3	3.09	0.047	12.7	0.200	1.64	0.052
4	0.396	0.000	0.421	0.000	0.409	0.000
Cutoff sensitivity (cutoff = 0.9)	≤ 0.04 U/mL		≤ 0.04 U/mL		≤ 0.1 IU/mL	

Specific performance data

Representative performance data on the analyzers are given below. Results obtained in individual laboratories may differ.

HBsAg II

Hepatitis B surface antigen

Precision

Precision was determined using Elecsys reagents, human sera and controls.

Elecsys 2010 and cobas e 411 analyzers						
Sample	Repeatability ^{b)}			Intermediate precision ^{c)}		
	Mean COI ^{d)}	SD COI	CV %	Mean COI	SD COI	CV %
HS ^{e)} , negative	0.333	0.026	7.7	0.429	0.043	10.1
HS, weakly positive	3.95	0.088	2.2	1.43	0.082	5.7
HS, positive	55.7	2.19	3.9	113	1.28	1.1
PreciControl HBSAG II 1	0.505	0.042	8.3	0.380	0.044	11.7
PreciControl HBSAG II 2	3.77	0.055	1.5	3.41	0.113	3.3

b) Repeatability = within-run precision (n = 21)

c) Intermediate precision = between-run (n = 10)

d) COI = cutoff index

e) HS = human serum

MODULAR ANALYTICS E170, cobas e 601 and cobas e 602 analyzers						
Sample	Repeatability ^{f)}			Intermediate precision ^{g)}		
	Mean COI	SD COI	CV %	Mean COI	SD COI	CV %
HS, negative	0.412	0.036	8.7	0.346	0.082	23.8
HS, weakly positive	2.42	0.048	2.0	2.34	0.141	6.0
HS, positive	284	3.27	1.2	280	11.2	4.0
PreciControl HBSAG II 1	0.455	0.038	8.5	0.439	0.049	11.2
PreciControl HBSAG II 2	3.59	0.075	2.1	3.61	0.126	3.49

f) Repeatability = within-run precision (n = 21)

g) Intermediate precision = within-laboratory (modified protocol (EP5-A) of the CLSI (Clinical and Laboratory Standards Institute): 6 times daily for 10 days (n = 60))

Analytical specificity

1596 samples containing potentially interfering substances were tested with the Elecsys HBsAg II assay comprising specimens:

- containing antibodies against HAV, HCV, HIV, HTLV, CMV, EBV, HSV, Rubella, Parvo virus, VZV, Toxoplasma gondii, Treponema pallidum, Borrelia, Listeriosis
- containing autoantibodies (ANA, SLE), elevated titers of rheumatoid factor or HAMA antibodies
- positive for Mumps, Measles, Malaria
- after vaccination against HBV and influenza
- from patients with monoclonal gammopathy and multiple myeloma/lymphoma, patients undergoing dialysis or patients suffering from alcoholic liver disease
- from pregnant women

No false positive result was found. 14 samples were found to be positive for HBsAg (1 out of each group of the HAV, HIV, HTLV and EBV antibody positive patients; 1 from a patient undergoing dialysis and 9 from pregnant women). 2 samples (1 after HBV vaccination and 1 with elevated RF) were initially positive, but negative after performing a second measurement. The overall specificity was 100 % (lower confidence limit 95 %, one-sided: 99.81 %).

Clinical sensitivity

A total of 1025 selected HBsAg confirmed positive samples in various stages of the disease were tested with the Elecsys HBsAg II assay. 1024 samples were correctly identified (1 sample was repeatedly negative

(COI 0.81-0.88), positively neutralized with the Elecsys HBsAg Confirmatory Test; negative in a 3rd HBsAg assay, anti-HBs negative, anti-HBe negative, HBeAg negative, anti-HBc positive). The sensitivity in that group of 1025 samples is 99.9 %.

A total of 156 genotyped samples (genotype A (30), B (8), C (11), C/E (1), D (68), E (17), F (17), G (3), not assigned (1)) and all known HBsAg subtypes (CNTS "Centre National de la Transfusion Sanguine", n = 9 subtype panels) were tested with the Elecsys HBsAg II assay. All of them were positive except for 6 samples (2 of genotype A, 1 of genotype D and 3 of genotype E) with negative or low HBV-DNA (also negative in other HBsAg tests). A total of 115 samples comprising different HBsAg mutations were tested with the Elecsys HBsAg II assay and compared to 3 registered HBsAg assays.

Mutant panel	Elecsys HBsAg II tested/positive
Native mutant panel 1 (strains displaying amino acid substitutions either linked to vaccine resistance, resistance to therapy with human HB immunoglobulin or impaired HBsAg reactivity)	41/40 ^{h)}
Native mutant panel 2 (strains displaying other amino acid changes)	24/24
Native mutant panel 3	19/17 ⁱ⁾
Recombinant mutant panel	31/31
Total	115/112

h) sample (mutation G145R) negative in all assays (COI 0.1-0.8); all measurements were performed in 1:40 dilution (FCS: fetal calf serum)

i) samples (mutation M133L/M143T/G145R and mutation T45S/I49R/113T114/I186P, respectively) negative in all assays tested; 1st mutation tested in 3 assays (COI 0.03-0.76), 2nd mutation tested in 4 assays (COI 0.03-0.78)

For 8 performance panels (Boston Biomedica, Inc.) the Elecsys HBsAg II assay shows a very good concordance with the data given in the respective product information (140 positives out of 150 samples tested). All positive assigned samples were positive with the Elecsys HBsAg II assay, resulting in a 100 % sensitivity.

Clinical specificity

The specificity of the Elecsys HBsAg II assay in a group of 6360 blood donors was found to be as follows: initially reactive (IR) specificity 99.91 %; repeatedly reactive (RR) specificity 99.98 %.

In the group of the 3593 daily routine samples (hospitalized patients, outpatients, pre-surgery, health care workers and anonymous testing), the specificity (IR and RR) was 99.88 %.

Group	Number	Initially reactive	Repeatedly reactive	Confirmed positive
Blood donors	6360	8	3	2
Hospitalized patients	3593	181	176 ^{j)}	122 ^{k)}

j) 5 samples could not be repeated due to insufficient sample volume

k) 55 samples could not be neutralized due to insufficient sample volume; 1 sample was negative with the Elecsys HBsAg II assay

Serum compared to plasma

Serum, Li-heparin plasma, EDTA plasma and citrate plasma samples were collected from 27 HBsAg-negative internal donors and partially spiked with HBsAg. The recovery for negative and positive plasma samples was compared to the corresponding serum sample.

Serum separation tubes (SST) compared to plasma separation tubes (PST)

Serum, SST serum and PST plasma samples were collected from 25 HBsAg-negative internal donors and partially spiked with HBsAg. The recovery for negative and positive SST-/PST-samples was compared to the corresponding serum sample.

HBsAg II

Hepatitis B surface antigen

cobas®

		Mean negative samples			Mean positive samples		
		COI	Recovery %	Range %	COI	Recovery %	Range %
N = 27	Serum	0.39			26.52		
	Li-heparin plasma	0.43	110	95-133	25.97	98	89-109
	EDTA plasma	0.41	107	86-136	26.95	102	90-110
	Citrate plasma	0.48	124	100-148	27.30	103	89-118
N = 25	Serum	0.42			22.88		
	SST	0.38	92	70-113	22.16	97	80-110
	PST	0.44	107	80-147	22.43	99	89-111

All measured sample materials are suitable for the Elecsys HBsAg II assay.

Seroconversion panels

Seroconversion sensitivity of the Elecsys HBsAg II assay has been shown by testing 56 commercial seroconversion panels in comparison to registered HBsAg assays. In all panels the Elecsys HBsAg II assay shows detection of seroconversion equal to or earlier than other HBsAg assays.

References

- Gerlich W. Viral Hepatitis. Section 2, Churchill Livingstone, Ed. Zuckermann AJ, Thomas HC, 1993:83-113.
- Hollinger FB. Hepatitis B virus. In Fields BN, Knipe DM (eds). Virology ed. 2 New York Raven Press 1990;2:2171-2236.
- Couroucé-Pauty AM, Plancon A, Soulier JP. Distribution of HBsAg Subtypes in the World. Vox Sang 1983;44:197-211.
- Gerlich W. Diagnostic Problems Caused by HBsAg Mutants – A Consensus Report of an Expert Meeting. Intervirology 2004;47:310-313.
- Hoofnagle JH, Di Bisceglie AM. Serologic Diagnosis of Acute and Chronic Viral Hepatitis. Seminars in Liver Disease 1991;11(2):73-83.
- Frösner G, Schomerus H, Wiedmann KH, et al. Diagnostic significance of quantitative HBsAg determination in acute and chronic hepatitis B infection. Eur J Clin Microbiol 1982;1:52-58.
- CDC. Prevention of Perinatal Transmission of Hepatitis B Virus: Prenatal Screening of all Pregnant Women for Hepatitis-B-Surface Antigen: Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR 1988;37:341-355.
- Stiko Recommendations, Bundesgesundheitsbl. 1996;1/96:32-42.
- Occupational Safety and Health Standards: bloodborne pathogens. (29 CFR Part 1910.1030). Fed. Register.
- Directive 2000/54/EC of the European Parliament and Council of 18 September 2000 on the protection of workers from risks related to exposure to biological agents at work.

For further information, please refer to the appropriate operator's manual for the analyzer concerned, the respective application sheets, the product information and the Method Sheets of all necessary components (if available in your country).

A point (period/stop) is always used in this Method Sheet as the decimal separator to mark the border between the integral and the fractional parts of a decimal numeral. Separators for thousands are not used.

Symbols

Roche Diagnostics uses the following symbols and signs in addition to those listed in the ISO 15223-1 standard.

CONTENT	Contents of kit
SYSTEM	Analyzers/Instruments on which reagents can be used
REAGENT	Reagent
CALIBRATOR	Calibrator



Volume after reconstitution or mixing

GTIN

Global Trade Item Number

COBAS, COBAS E, ELECSYS and PRECICONTROL are trademarks of Roche.

All other product names and trademarks are the property of their respective owners.

Significant additions or changes are indicated by a change bar in the margin.

© 2014, Roche Diagnostics

CE 0123



Roche Diagnostics GmbH, Sandhofer Strasse 116, D-68305 Mannheim
www.roche.com

